<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Weidner P</dc:creator>
  <dc:creator>Söhn M</dc:creator>
  <dc:creator>Schroeder T</dc:creator>
  <dc:creator>Helm L</dc:creator>
  <dc:creator>Hauber V</dc:creator>
  <dc:creator>Gutting T</dc:creator>
  <dc:creator>Betge J</dc:creator>
  <dc:creator>Röcken C</dc:creator>
  <dc:creator>Rohrbacher FN</dc:creator>
  <dc:creator>Pattabiraman VR</dc:creator>
  <dc:creator>Bode JW</dc:creator>
  <dc:creator>Seger R</dc:creator>
  <dc:creator>Saar D</dc:creator>
  <dc:creator>Nunes-Alves A</dc:creator>
  <dc:creator>Wade RC</dc:creator>
  <dc:creator>Ebert MPA</dc:creator>
  <dc:creator>Burgermeister E</dc:creator>
  <dc:date>2020</dc:date>
  <dc:description xmlns:ns0="xml" ns0:lang="en">Peroxisome proliferator-activated receptor-gamma (PPARγ) is a transcription factor drugable by agonists approved for treatment of type 2 diabetes, but also inhibits carcinogenesis and cell proliferation in vivo. Activating mutations in the Kirsten rat sarcoma viral oncogene homologue (KRAS) gene mitigate these beneficial effects by promoting a negative feedback-loop comprising extracellular signal-regulated kinase 1/2 (ERK1/2) and mitogen-activated kinase kinase 1/2 (MEK1/2)-dependent inactivation of PPARγ. To overcome this inhibitory mechanism, we searched for novel post-translational regulators of PPARγ. Phosphoinositide phosphatase Myotubularin-Related-Protein-7 (MTMR7) was identified as cytosolic interaction partner of PPARγ. Synthetic peptides were designed resembling the regulatory coiled-coil (CC) domain of MTMR7, and their activities studied in human cancer cell lines and C57BL6/J mice. MTMR7 formed a complex with PPARγ and increased its transcriptional activity by inhibiting ERK1/2-dependent phosphorylation of PPARγ. MTMR7-CC peptides mimicked PPARγ-activation in vitro and in vivo due to LXXLL motifs in the CC domain. Molecular dynamics simulations and docking predicted that peptides interact with the steroid receptor coactivator 1 (SRC1)-binding site of PPARγ. Thus, MTMR7 is a positive regulator of PPARγ, and its mimicry by synthetic peptides overcomes inhibitory mechanisms active in cancer cells possibly contributing to the failure of clinical studies targeting PPARγ.</dc:description>
  <dc:format>application/pdf</dc:format>
  <dc:identifier>https://sonar.ch/global/documents/238687</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1038/s41389-020-0238-8</dc:relation>
  <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/32522977</dc:relation>
  <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
  <dc:source>Oncogenesis. - 2020</dc:source>
  <dc:subject xmlns:ns1="xml" ns1:lang="en">Cancer Research</dc:subject>
  <dc:subject xmlns:ns2="xml" ns2:lang="en">Molecular Biology</dc:subject>
  <dc:title xmlns:ns3="xml" ns3:lang="en">Myotubularin-related protein 7 activates peroxisome proliferator-activated receptor-gamma.</dc:title>
  <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
</oai_dc:dc>
